Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes

American Heart Journal

Volumn 156, Issue 5, 2008, Pages 826-832

  Cannon, Christopher P ^a   Giugliano, Robert P ^a   Blazing, Michael A ^b   Harrington, Robert A ^b   Peterson, John L ^b   Sisk, Christine McCrary ^c   Strony, John ^c   Musliner, Thomas A ^c   McCabe, Carolyn H ^a   Veltri, Enrico ^c   Braunwald, Eugene ^a   Califf, Robert M ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; EZETIMIBE PLUS SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; HUMANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMVASTATIN; TREATMENT OUTCOME;

EID: 50949102416     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.07.023     Document Type: Article

References (32)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
2. Sacks F.M., Tonkin A.M., Shepherd J., et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 102 (2000) 1893-1900
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet 360 (2002) 7-22
4. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
5. Ballantyne C.M. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 82 (1998) 3Q-12Q
6. O'Keefe Jr. J.H., Cordain L., Harris W.H., et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 43 (2004) 2142-2146
7. Hooper L., Summerbell C.D., Higgins J.P., et al. Dietary fat intake and prevention of cardiovascular disease: systematic review. BMJ 322 (2001) 757-763
8. Iestra J.A., Kromhout D., van der Schouw Y.T., et al. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation 112 (2005) 924-934
9. Lipid Research Clinics Program. JAMA 252 (1984) 2545-2548
10. Davidson M.H. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation 111 (2005) 2280-2281
11. Robinson J.G., Smith B., Maheshwari N., et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 46 (2005) 1855-1862
12. Buchwald H., Varco R.L., Matts J.P., et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 323 (1990) 946-955
13. Cannon C.P., Steinberg B.A., Murphy S.A., et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48 (2006) 438-445
14. Grundy S.M., Cleeman J.I., Merz C.N.B., et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110 (2004) 227-239
15. Sudhop T., Lutjohann D., Kodal A., et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106 (2002) 1943-1948
16. Kosoglou T., Meyer I., Veltri E.P., et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 54 (2002) 309-319
17. Davis Jr. H.R., Zhu L.J., Hoos L.M., et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 279 (2004) 33586-33592
18. Gagne C., Bays H.E., Weiss S.R., et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90 (2002) 1084-1091
19. Ballantyne C.M., Blazing M.A., King T.R., et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 93 (2004) 1487-1494
20. Ballantyne C.M., Abate N., Yuan Z., et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 149 (2005) 464-473
21. Pearson T.A., Denke M.A., McBride P.E., et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 80 (2005) 587-595
22. Bays H.E., Ose L., Fraser N., et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 26 (2004) 1758-1773
23. Sager P.T., Capece R., Lipka L., et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 179 (2005) 361-367
24. Kastelein J.J., Akdim F., Stroes E.S., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008) 1431-1443
25. Giugliano R.P., Newby L.K., Harrington R.A., et al. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome-study design and rationale. Am Heart J 149 (2005) 994-1002
26. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 106 (2002) 1024-1028
27. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681-1690
28. Sniderman A.D. Is there value in liver function test and creatine phosphokinase monitoring with statin use?. Am J Cardiol 94 Suppl. 9A (2004) 30F-34F
29. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
30. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
31. Ridker P.M., Morrow D.A., Rose L.M., et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of LDL-C<70 mg/dl and CRP <2 mg/L: An analysis of the PROVE-IT TIMI 22 Trial. J Am Coll Cardiol 45 (2005) 1644-1648
32. Kastelein J.J., Sager P.T., de Groot E., et al. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J 149 (2005) 234-239